AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05226598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 100 mg/vial administered as IV infusion Days 1, 8, and 15 of each 21-day cycle for 4 administrations
Study NCT05086770 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelatin microsphere (Nexsphere™)
Description: Gelatin microsphere (Nexsphere™) is a yellow powder, made of 100% hydrophilic gelatin. It is used to make a suspension by mixing a contrast agent and physiological saline. The indications for gelatin microsphere are hepatic artery chemoembolization, uterine artery embolization, prostate artery embolization, and treatment of various hemorrhagic diseases. It physically embolizes blood vessels and is decomposed within 4-8 weeks after intravascular injection.
Study NCT05226598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/vial administered as IV infusion Q3W until progression, intolerable adverse event (AE), or participant or physician decision
Study NCT05226598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/vial administered as IV infusion Q3W until progression, intolerable adverse event (AE), or participant or physician decision
Study NCT05226598 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab 25 mg/mL administered as IV infusion Q3W for up to 35 administrations
Study NCT05281276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide
Description: During the run-in period, the patients will take a single dose of chidamide on Day 3. In a 28-day treatment cycle, the dosing schedule is four/six table (20/30mg) BIW .
Study NCT06010706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised physical therapy manual exercise program.
Description: 1. Mobilization Techniques :~   The joint mobilization technique will be the anterior-posterior glide of the talus. The participant will be positioned in supine or long sitting.~2. Stretching Exercise:~   Passive stretching with therapist assistance was used for ankle dorsiflexion with the knee both flexed and extended. Force during passive stretching was modified to patient tolerance. Each participant flexed the knee slightly while standing on a 10° incline board. The participant was asked to slightly flex both knees until a stretch was felt in the calf muscle.~3. Strengthening Exercise:~The resistance training protocol will be based on the progressive resistance training principle and was a modification of the protocol used by Frontera et al \[10\] in older men. Plantar-flexion resistance training will be performed on a customized hydraulic apparatus, which provide a constant resistance over the entire ROM and allow for concentric as well as eccentric.
Study NCT06010706 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercise, ROM, Strengthening exercises.
Description: Patients at the control group will receive instruction for home based exercise program of physical therapy exercise. The home program primarily consisted of exercises targeting deficits in joint ROM, muscle flexibility and strength, and balance.
Study NCT05281276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: During the run-in period, the patients will take a single dose of celecoxib on Day 1. In a treatment cycle, the dosing schedule is one capsule(200 mg) daily.
Study NCT05335434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THOR LX2.3 with LED Lollipop
Description: The intraoral PBMT device will be placed inside of the mouth to deliver the therapeutic light. Each treatment is approximately 2-3 minutes in duration. PBMT will be administered daily starting from the start of conditioning through day +20, or discharge if prior to day +20, with 27 consecutive days defined as a maximum PBMT treatment duration
Study NCT05086770 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Embosphere
Description: Tris-acryl gelatin microspheres (Embosphere Microspheres) are biocompatible and nonresorbable with cell adhesion properties for complete and durable mechanical occlusion.
Study NCT05168449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Application
Description: mobile phone applications directed to chronic kidney disease patients to improve their medication.
Study NCT06266754 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral polio vaccine
Description: Standard oral polio vaccine
Study NCT06266754 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline 0.9%
Study NCT05318937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-718
Description: Softgel capsules
Study NCT05318937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAGE-718-matching placebo
Description: Softgel capsules
Study NCT05085574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: 80 mg tablet, QID for 14 days
Study NCT05085574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400 mg (initial dose), then 200 mg capsule, BID for 5 days
Study NCT05085574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet, QID for 14 days; capsule, BID for 5 days
Study NCT05371730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCR300
Description: Intravenous infusion of NK cells（NCR300）
Study NCT06064149 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CARE-PC Web-Based Application
Description: The CARE-PC app is a pragmatic, patient-oriented, web-based application that enables the education of patients regarding cardiovascular (CV) risks and collects CV and prostate cancer-related risk variables and CV care access data from prostate cancer patients receiving ADT.
Study NCT06325124 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle energy technique
Description: They would be receiving treatment as follow:~Muscle energy technique of hamstring and gastro-soleus. Frequency: 10 reps 3 times/week for 4 consecutive weeks Intensity starting from 20% to 50% resistance across barrier provided by Physical therapist Conventional PT including 1-cervical isometric exercises 2-Transcutaneous Electrical Nerve Stimulation (TENS) for 1o minutes 3-hot pack for 10 minutes 4-Stretching exercise for suboccipitals, sternocleidomastoid 5-gentle stretching of calf and hamstrings.
Study NCT06325124 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional PT
Description: They would be receiving treatment as follow:~Conventional PT including 1-cervical isometric exercises 2-Transcutaneous Electrical Nerve Stimulation (TENS) for 1o minutes 3-hot pack for 10 minutes 4-Stretching exercise for suboccipitals, sternocleidomastoid 5-gentle stretching of calf and hamstrings.
Study NCT04694703 — intervention group
Intervention type: DRUG
Intervention: Covid-19 group
Description: Routine COVID-19 treatment
Study NCT06713057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide+Pemetrexed+5-Fluorouracil
Description: IV or PO
Study NCT06713057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide+Doxorubicin+5-Fluorouracil
Description: IV or PO
Study NCT06713057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vindesine + Cisplatin
Description: IV or PO
Study NCT06713057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin + Cisplatin
Description: IV or PO
Study NCT06713057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin + Cyclophosphamide + Cisplatin
Description: IV or PO
Study NCT05624762 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-Intensity Focused Ultrasound (LIFU)
Description: LIFU device (LCA200; Chongqing Haifu Medical Technology Co., Ltd., Chongqing, China).
Study NCT05624762 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Low-Intensity Focused Ultrasound
Description: Sham Low-Intensity Focused Ultrasound
Study NCT05498090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate 145 mg
Description: Fenofibrate 145 mg PO daily for 4 weeks
Study NCT06077279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Horticultural Therapy Program
Description: Horticultural Therapy Program Is selected plant therapy
Study NCT06509984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast treatment
Description: treatment of apremilast
Study NCT05703165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: animal-assisted intervention
Description: horse-assisted intervention
Study NCT05703165 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: animal-assisted intervention
Description: horse-assisted intervention
Study NCT05703165 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: watching the countryside
Description: just watching the countryside
Study NCT05701631 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Radiomic model
Description: Radiomic model for PCP diagnosis
Study NCT05625867 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychological and quality of life questionnaires
Description: At 4/5 months and at 9 months
Study NCT05625867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological and quality of life questionnaires
Description: At 4/5 months and at 9 months
Study NCT05625867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interdisciplinary consultation at 4/5 months
Description: About ten days after the questionnaires were administered
Study NCT06449391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RAI
Description: Immediate implantation
Study NCT05922709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS12192 capsule
Description: Participants receive CS12192 orally single or multiple doses
Study NCT05922709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Participants receive placebo matching CS12192 orally single or multiple doses
Study NCT05296941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brush sampling
Description: Brush sampling instead of surgical biopsy for control of reaccurance
Study NCT05296941 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brush sampling
Description: Brush sampling instead of surgical biopsy for control of reaccurance
Study NCT05542849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose Tablets 50mg
Description: Acarbose is an Alpha-glucosidase inhibitor. It is a compound also known under the names Glucobay, Precose, and Prandase. Acarbose is used (with diet and other medications) to treat type 2 diabetes (condition in which the body does not use~insulin normally and therefore cannot control the amount of sugar in the blood). Acarbose works by blocking α- glucosidase, which breaks down starch (aka amylose) into glucose (sugar) into your blood. Slowing food digestion~helps keep blood glucose from rising very high after meals.
Study NCT06210581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Exercise Program Group
Description: The exercise programs will performed with the physiotherapist. The treatment programs of the patients will start with warm-up exercises and continue with aerobic exercises. Strengthening exercises will be performed in lying, sitting and standing positions. Body weight or free weight will be used for strengthening exercises. Balance exercises will be performed in sitting and standing positions and will be performed with or without support according to the patients conditions. The treatment sessions will be terminated by performing relaxation exercises combined with stretching and breathing exercises.
Study NCT06210581 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Internet Based Exercise Program Group
Description: Patients who are in the internet-based exercise program group will register cite ''https://www.telenororehab.com /'' which is web- based physiotherapy program for exercises. After the first evaluation patients will be given a username and password to log in to the system.~Before starting the exercise programs, the pages on how patients can log in to the system, how they can reach the physiotherapist through the system and how they can find individual exercise programs will be shown before the study. After logging in to their own pages, patients will be able to access video-based exercise programs that have been specially prepared for them. Patients in the Internet-based exercise program group will also be given the same exercise programs as the supervised exercise program group. The entry-exit times of patients to the system and the duration of maintaining exercise programs will be controlled from the administrator section on the system.
Study NCT04288271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Intervention
Description: Intervention:~* Adherence Support Team (patient, parent or a significant other, Coach)~* Standardized educational videos on immunosuppressive medications, rejection, and improving adherence~* Identification of adherence barriers, self-efficacy for medication-taking, and allocation of treatment responsibility~* 'Action-Focused Problem-Solving' to address barriers selected as most important by the patient~Device:~* Electronic pillbox monitoring with text message and/or audio/visual dose reminders and access to e-pillbox website~* Feedback of electronic monitoring data at increasing intervals between initiation of the intervention at 4-week and exit at 14-week.
Study NCT04288271 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Healthy living education intervention
Description: Intervention:~* Standardized educational videos on immunosuppressive medications, rejection, and improving adherence~* Healthy living topic discussion at increasing intervals between 4-wk and 14-wk visits~* 'Action-Focused Problem-Solving' to address barriers on healthy living topic selected by the patient~Device:~• Electronic adherence monitoring without dose reminders or feedback (enrollment to 14w)
Study NCT05025254 — intervention group
Intervention type: OTHER
Intervention: Neurocognitive testing
Description: We are assessing several cognitive domains and have made minor adaptations (reducing the total number of trials or lengthening response windows) to several standard neuropsychology tests including measures of executive function, working memory, visuospatial function, declarative memory, reward processing, response inhibition.~Overall, the tests we use follow a standard set-up: participants are shown stimuli on the screen and are asked to provide a response using either a keyboard or a mouse, based on a specific set of instructions. We always provide a detailed set of on-screen instructions and a practice phase. In some cases, information about performance is provided in the form of points, in other cases, none is provided.
Study NCT05284877 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: The study is an observational study without intervention.
Study NCT05530785 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: radiotherapy combined with sintilimab and bevacizumab biosimilar
Description: After signing informed consent, patients received sintilimab 200 mg intravenously on the first day of each cycle, Q3W; Bevacizumab biosimilar 7.5mg/kg was administered intravenously on the first day of each cycle, Q3W; Concurrent radiotherapy (single dose 3-8Gy, times 3-10, total dose 20-50Gy; The duration of radiotherapy was completed between the first administration of sintilimab and the second administration of bevacizumab, but it should be noted that the interval between before and after the administration of sintilimab and bevacizumab was at least 3 days.
Study NCT06713057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel + Doxorubicin
Description: IV or PO
Study NCT06713057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel + Carboplatin
Description: IV or PO
Study NCT06713057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel + Doxorubicin
Description: IV or PO
Study NCT06713057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel + Cisplatin
Description: IV or PO
Study NCT06713057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine alone
Description: IV or PO
Study NCT06713499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1819 injection
Description: SHR-1819 injection.
Study NCT06713252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art therapy
Description: Through music, painting, dance and other forms, art therapy can not only help patients regulate their emotions, relieve anxiety and depression, but also activate different areas of the brain to promote neuroplasticity, thereby promoting the recovery of motor function
Study NCT06713252 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular therapy
Description: Standard treatment
Study NCT06713408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental (Music)
Description: Audio recordings consisting of pentatonic music and neva makam will be uploaded to the patients' phones by the researcher. Patients will be advised to listen to these music during the period they receive chemotherapy, and they will also be asked to listen to these music in at least 15-20 minute sessions per day and for at least 3 days during the week following chemotherapy.
Study NCT06713408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental (Affirmation)
Description: Patients in this group will be asked to listen to the audio recording with pentatonic music and neva makam in the background, along with the affirmation sentences provided in the appendix. Patients will be advised to listen to these music during the period they receive chemotherapy, and they will also be asked to listen to these music in at least 15-20 minute sessions per day and for at least 3 days during the week following chemotherapy.
Study NCT04933708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Labor Podcast
Description: Listening to podcasts.~Topics include:~Labor Anesthesia, Induction of Labor, Second Stage of Labor, Reasons for Cesarean Section, Postpartum Recovery, Complications of Labor and Birth
Study NCT06713187 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: interleukin 23
Description: assessment of interleukin 23 in Sera of patients using ELIZA
Study NCT06711393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Traditional home exercise including balance and muscle strength training 15 minutes at the time and three times over the week. In addition, game-based exercises 15 minutes at the time and three times over the week.
Study NCT06711393 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise as usual
Description: Traditional home exercise including balance and muscle strength training 15 minutes at the time and three times over the week without exergaming.
Study NCT06706882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Training: VIRTRAEL/LUCCIDY
Description: Cognitive stimulation of the different cognitive functions to be addressed will be conducted in the following sessions:~* Session 1: Shopping lists. Balls. Gift shopping. Long-term memory of the Shopping List.~* Session 2: Disordered objects. Whats different? Semantic series. Logical series. Puzzle pieces. Semantic analogies.~* Session 3: Classifiable objects. Gift shopping. Bag of objects.~* Session 4: Shopping lists. Balls. Disordered objects. Long-term memory of the Shopping List.~* Session 5: Semantic series. Logical series. Puzzle pieces. Semantic analogies. Gift shopping.~* Session 6: Classifiable objects. Bag of objects. Disordered objects.~* Session 7: Shopping lists. Semantic series. Logical series. Puzzle pieces. What\&amp;#39;s different? Semantic analogies. Long-term memory of the Shopping List.~* Session 8: Disordered objects. Gift shopping. Balls.~* Session 9: Bag of objects. Semantic series. Logical series. Whats different? Semantic analogies. Classifiable objects.
Study NCT06706882 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Standard Training: Reflection Group (TAU) (Andalusian Institute of Women, 2010)
Description: This 9-session program explores how societal norms shape women\&amp;#39;s roles and identities. In Session 1, it discusses how women are socially positioned as caretakers in relationships and introduces the concept of the self in relation. Session 2 delves into gender conflicts, focusing on the tension between societal demands and personal desires. Session 3 explores guilt when women fail to meet expected roles, and the fear of being selfish when prioritizing their own needs. Session 4 examines how dependence is fostered by seeking external validation for self-worth. Session 5 critiques romantic love as a cultural tool to prioritize men desires over women. Session 6 analyzes how intimate partner violence (IPV) emerges as a means to maintain power imbalances in relationships. Session 7 looks at the family role in socializing women, while Session 8 explores fears of abandonment. Finally, Session 9 focuses on building life skills and concludes the program.
Study NCT06707324 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: drug injected between the rectus abdominis muscle and the transversus abdominis muscle
Description: 20 ml of 0.25% bupivacaine + 8 mg dexamethasone between the rectus abdominis muscle and the transversus abdominis muscle on both sides
Study NCT06707324 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: drug injected in the external oblique intercostal plane on both sides
Description: 20 ml of 0.25% bupivacaine+ 8 mg dexamethasone into the external oblique intercostal plane on both sides
Study NCT05144217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule per day of placebo
Study NCT05144217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2x 140 mg per day
Description: 2 capsule per day of silimarit